Alto Neuroscience Inc (ANRO) ニュース

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

– Data generated from Alto’s precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...

Form 8-K - Current report

Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder

– Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants

– Despite its reported benefits for aspects of cognition, vortioxetine does not demonstrate greater clinical efficacy in major depressive...